Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 76-80

  Campbell, Nicholas P ^a   Kunnavakkam, Rangesh ^a   Leighl, Natasha ^b   Vincent, Mark D ^c   Gandara, David R ^d   Koczywas, Marianna ^e   Gitlitz, Barbara J ^f   Agamah, Edem ^g   Thomas, Sachdev P ^h   Stadler, Walter M ^a   Vokes, Everett E ^a   Kindler, Hedy L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Central Illinois Hematology/Oncology   (United States)

^h Oncology/Hematology Associates   (United States)

Author keywords

Cediranib; Hypertension; Mesothelioma; Vascular endothelial growth factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; CEDIRANIB; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPONATREMIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; THROMBOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84866158896     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.06.011     Document Type: Article

References (25)

1. Campbell N.P., Kindler H.L. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 2011, 32:102-110.
2. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
3. Ceresoli G.L., Zucali P.A., De Vincenzo F., Gianoncelli L., Simonelli M., Lorenzi E., et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011, 72:73-77.
4. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
5. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62:179-213.
6. Loganathan S., Kanteti R., Siddiqui S.S., El-Hashani E., Tretiakova M., Vigneswaran H., et al. Role of protein kinase C beta and vascular endothelial growth factor receptor in malignant pleural mesothelioma: therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog 2011, 10:4.
7. Kindler H.L., Karrison T.G., Gandara D.R., Lu C., Krug L.M., Stevenson J.P., et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012, 30:2509-2515.
8. Kao S.C., Harvie R., Paturi F., Taylor R., Davey R., Abraham R., et al. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer 2011.
9. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
10. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrqiebel U., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:3045-3054.
11. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
12. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
14. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
15. Robinson E.S., Khankin E.V., Karumanchi S.A., Humphreys B.D. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010, 30:591-601.
16. Bono P., Elfving H., Utriainen T., Osterlund P., Saarto T., Alanko T., et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009, 20:393-394.
17. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
18. Scartozzi M., Galizia E., Chiorrini S., Giampieri R., Berardi R., Pierantoni C., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20:227-230.
19. Dahlberg S.E., Sandler A.B., Brahmer J.R., Schiller J.H., Johnson D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010, 28:949-954.
20. Garland L.L., Chansky K., Wozniak A.J., Tsao A.S., Gadgeel S.M., Verschraegen C.F., et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011, 6:1938-1945.
21. Kindler H., Vogelzang N.J., Chien K., Stadler W.M., Karczmar G., Heimann R., et al. SU5416 in malignant mesothelioma: a University of Chicago Phase II Consortium Study. J Clin Oncol 2001, 20:1359. [abstract].
22. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291-296.
23. Nowak A., Millward M., Francis R.J., Hasani A., van der Schaaf A.A., Seguard T., et al. Final results of a phase II trial of sunitinib as second-line therapy in malignant pleural mesothelioma. J Clin Oncol 2010, 28:7036. [abstract].
24. Dubey S., Janne P.A., Krug L., Pang H., Wang X., Heinze R., et al. A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307. J Thorac Oncol 2010, 5:1655-1661.
25. Jahan T., Gu L., Kratzke R., Dudek A., Otterson G.A., Wang X., et al. Vatalanib in malignant mesothelioma: a Phase II trial by the cancer and leukemia group b (CALGB 30107). Lung Cancer 2012, 76:393-396.